Randomized placebo-controlled evaluation of intramuscular interferon beta treatment of recurrent human papillomavirus

González-Sánchez, José Luis; Martínez-Chéquer, Juan Carlos; Hernandez-Celaya, Maria Eugenia; Barahona-Bustillos, Edgar; Andrade-Manzano, Alejandro

doi:10.1016/s0029-7844(00)01201-1

Cited by 19 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 56% of the women with persistent hrHPV infections remained positive after a year of follow-up, and the mean time for clearance of hrHPV infection was close to sixteen months [16,17].…”

Section: Discussionmentioning

confidence: 99%

REBACIN® is an optional intervention for persistent high-risk human papillomavirus infection: a retrospective analysis of 364 patients

Ming

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Persistent high-risk human papillomavirus (hrHPV) infection is a crucial cause of cervical cancer, for which optimal pharmacological intervention remains unavailable. This study aimed at evaluating the therapeutic efficacy of REBACIN® in patients with persistent hrHPV infection.Methods: This study is a combination of a retrospective analysis and a meta-analysis. The retrospective analysis included 364 patients who were persistently infected with HPV for at least twelve months, between September 2015 and February 2019, and only received REBACIN® intervention. HPV DNA typing, HC2 hrHPV DNA, and ThinPrep cytologic tests were performed before and after REBACIN® intervention, to evaluate the therapeutic efficacy. The meta-analysis included trials evaluating the therapeutic efficacy of interferons.Results: After a follow-up period of three to six months, the overall effective rate of REBACIN® was 74.73% (272/364), which was higher than that of interferon (61.50%). The efficacy of REBACIN® was correlated with HPV type (OR: 0.549, 95% CI: 0.367–0.822, P < 0.05) and pretreatment cytology (OR: 0.358, 95% CI: 0.173–0.739, P < 0.05).Conclusions: REBACIN® is potently efficacious at clearing persistent hrHPV infection; hence, it can serve as an optional intervention for persistent hrHPV infection.

show abstract

Section: Discussionmentioning

confidence: 99%

REBACIN® is an optional intervention for persistent high-risk human papillomavirus infection: a retrospective analysis of 364 patients

Ming

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…IFN-b, like IFN-a, is classified as a type I interferon and can effectively inhibit tumor cell growth by inducing cell differentiation and accumulation of transformed cells in S-phase, thereby effectively inducing failure to progress to G2 and M and promoting apoptosis [ 17 ]. IFN-b, administered either alone or in combination with other agents as intramuscular injections, has been used for more than 10 years to treat HPVs [ 18 ]. In a meta-analysis, Yang et al [ 19 ] reported that, of 1,445 cases of genital warts treated with IFN-b, 27.4% to 44.4% were completely cured; there are also reports that IFN-b is effective in treating CIN-related, recurrent HPV lesions [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

“…IFN-b, administered either alone or in combination with other agents as intramuscular injections, has been used for more than 10 years to treat HPVs [ 18 ]. In a meta-analysis, Yang et al [ 19 ] reported that, of 1,445 cases of genital warts treated with IFN-b, 27.4% to 44.4% were completely cured; there are also reports that IFN-b is effective in treating CIN-related, recurrent HPV lesions [ 18 ]. Studies on the effects of siRNAs and IFN-b in HPV infection-related cancers have not been attempted.…”

Section: Discussionmentioning

confidence: 99%

Long (27-nucleotides) small inhibitory RNAs targeting E6 protein eradicate effectively the cervical cancer cells harboring human papilloma virus

Cho¹,

Lee

Kim

et al. 2015

Obstet Gynecol Sci

View full text Add to dashboard Cite

ObjectiveThis study was to identify small inhibitory RNAs (siRNAs) that are effective in inhibiting growth of cervical cancer cell lines harboring human papilloma virus (HPV) and to examine how siRNAs interact with interferon beta (IFN-β) and thimerosal.MethodsThe HPV18-positive HeLa and C-4I cell lines were used. Four types of siRNAs were designed according to their target (both E6 and E7 vs. E6 only) and sizes (21- vs. 27-nucleotides); Ex-18E6/21, Ex-18E6/27, Sp-18E6/21, and Sp-18E6/27. Each siRNA-transfected cells were cultured with or without IFN-b and thimerosal and their viability was measured.ResultsThe viabilities of HPV18-positive tumor cells were reduced by 21- and 27-nucleotide siRNAs in proportion to the siRNA concentrations. Of the two types of siRNAs, the 27-nucleotide siRNA constructs showed greater inhibitory efficacy. Sp-18E6 siRNAs, which selectively downregulates E6 protein only, were more effective than the E6- and E7-targeting Ex-18E6 siRNAs. siRNAs and IFN-β showed the synergistic effect to inhibit HeLa cell survival and the effect was proportional to both siRNA and IFN-β concentrations. Thimerosal in the presence of siRNA exerted a dose-dependent inhibition of C-4I cell survival. Finally, co-treatment with siRNA, IFN-β, and thimerosal induced the most profound decrease in the viability of both cell lines.ConclusionLong (27-nucleotides) siRNAs targeting E6-E7 mRNAs effectively reduce the viability of HPV18-positive cervical cancer cells and show the synergistic effect in combination with IFN-b and thimerosal. It is necessary to find the rational design of siRNAs and effective co-factors to eradicate particular cervical cancer.

show abstract

“…The therapeutic effects of interferon β (type-I interferon) on recurrent HPV infection lesions have been clinically proven, especially in patients with cervical intraepithelial neoplasia (CIN) [306]. Type I IFN strongly induces p56 expression, and p56 binds the E1 protein of several HPV serotypes [307].…”

Section: Viral-specific Nuclear Transport Inhibitorsmentioning

confidence: 99%

How SARS-CoV-2 and Other Viruses Build an Invasion Route to Hijack the Host Nucleocytoplasmic Trafficking System

Sajidah

Lim

Wong

2021

Cells

View full text Add to dashboard Cite

The host nucleocytoplasmic trafficking system is often hijacked by viruses to accomplish their replication and to suppress the host immune response. Viruses encode many factors that interact with the host nuclear transport receptors (NTRs) and the nucleoporins of the nuclear pore complex (NPC) to access the host nucleus. In this review, we discuss the viral factors and the host factors involved in the nuclear import and export of viral components. As nucleocytoplasmic shuttling is vital for the replication of many viruses, we also review several drugs that target the host nuclear transport machinery and discuss their feasibility for use in antiviral treatment.

show abstract

Randomized placebo-controlled evaluation of intramuscular interferon beta treatment of recurrent human papillomavirus

Abstract: Intramuscular injections of interferon beta were effective for treating recurrent HPV lesions, particularly when associated with CIN. The only side effects were mild and controllable.

Cited by 19 publications

References 19 publications

REBACIN® is an optional intervention for persistent high-risk human papillomavirus infection: a retrospective analysis of 364 patients

REBACIN® is an optional intervention for persistent high-risk human papillomavirus infection: a retrospective analysis of 364 patients

Long (27-nucleotides) small inhibitory RNAs targeting E6 protein eradicate effectively the cervical cancer cells harboring human papilloma virus

How SARS-CoV-2 and Other Viruses Build an Invasion Route to Hijack the Host Nucleocytoplasmic Trafficking System

Contact Info

Product

Resources

About